Evidence map›Paper›PMID 32135127›Full record

ReviewThe lancet. Gastroenterology & hepatology2020

Early detection of pancreatic cancer.

Stephen P Pereira, Lucy Oldfield, Alexander Ney, Phil A Hart, Margaret G Keane, Stephen J Pandol, Debiao Li, William Greenhalf, Christie Y Jeon, Eugene J Koay and 4 more

3 registry-linked trialsOpen access · greenAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in The lancet. Gastroenterology & hepatology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 3 registered trials, which are not on this map. Cited by 274 papers, 8 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
274citing papers in PubMed, 8 pooled it
22.4field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT04743479 recruitingnot on this map

Artificial Intelligence-based Health Information Management System and Key Technology Study of Early Screening and Hierarchical Diagnosis and Treatment of Pancreatic Cancer

TypeobservationalSponsorChanghai HospitalRan2020 to 2030Enrolled5,000ConditionsPancreatic Cancer, Diabetes, Familial Pancreatic Cancer, Pancreatic Cystic NeoplasmArmshigh-resolution MRI/CT examinations
NCT06638866 recruitingnot on this mapstarted 2024, after this paper: background citation

Artificial Intelligence-based Health Information Management System and Key Technology Study of Early Screening and Hierarchical Diagnosis and Treatment of Pancreatic Cancer

Typeobservational_patient_registrySponsorChanghai HospitalRan2024 to 2030Enrolled5,000ConditionsPancreatic Cancer, Pancreatic Ductal Adenocarcinoma, Pancreatic Intraepithelial Neoplasias, Intraductal Papillary Mucinous NeoplasmArmsPDAC, Pancreatic precursor lesions
NCT07117045 recruitingnot on this mapstarted 2025, after this paper: background citation

Artificial Intelligence-powered Low-Dose Computed Tomography for Screening of Pancreatic Cancer

TypeobservationalSponsorChanghai HospitalRan2025 to 2032Enrolled400,000ConditionsPancreatic Cancer, Intraductal Papillary Mucinous Neoplasm, High-grade Pancreatic Intraepithelial Neoplasia, PDAC - Pancreatic Ductal AdenocarcinomaArmsDiagnostic Evaluation for Positive AI Findings
3 · Its place in the literature

Who cites it

274 citing papers in PubMed, 8 syntheses or guidelines pooled it, 450 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Passion fruit (Frontiers in nutrition · 2024
    Pooled it
  7. Pooled it
  8. Pooled it
  9. Review
  10. Article
  11. Article
  12. Exploring correlations of CA19-9 with serum enzyme ratios: can layered biomarker strategies enhance prognostic accuracy in pancreatic cancer?Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2026
    Review
  13. Review
  14. Article
  15. Article
  16. Review
  17. Article
  18. Article
  19. Article
  20. Article

214 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 6 institutions in 2 countries.

Stephen P PereiraInstitute for Liver and Digestive Health, University College London, London, UK.
Lucy OldfieldDepartment of Molecular and Clinical Cancer Medicine, Institute of Translational Medicine, University of Liverpool, UK.
Alexander NeyInstitute for Liver and Digestive Health, University College London, London, UK.
Phil A HartDivision of Gastroenterology, Hepatology, and Nutrition, Ohio State University Wexner Medical Center, Columbus, OH, USA.
Margaret G KeaneDivision of Gastroenterology and Hepatology, Johns Hopkins University, Baltimore, MD, USA.
Stephen J PandolDepartment of Medicine, Division of Digestive and Liver Diseases, Cedars-Sinai Medical Center, Los Angeles, CA, USA.
Debiao LiCedars-Sinai Medical Center, Los Angeles, CA, USA.
William GreenhalfDepartment of Molecular and Clinical Cancer Medicine, Institute of Translational Medicine, University of Liverpool, UK.
Christie Y JeonDepartment of Medicine, Division of Digestive and Liver Diseases, Cedars-Sinai Medical Center, Los Angeles, CA, USA.
Eugene J KoayUniversity of Texas MD Anderson Cancer Center, Houston, TX, USA.
Christopher V AlmarioDepartment of Medicine, Division of Digestive and Liver Diseases, Cedars-Sinai Medical Center, Los Angeles, CA, USA.
Christopher HalloranDepartment of Molecular and Clinical Cancer Medicine, Institute of Translational Medicine, University of Liverpool, UK.
Anne Marie LennonDivision of Gastroenterology and Hepatology, Johns Hopkins University, Baltimore, MD, USA.
Eithne CostelloDepartment of Molecular and Clinical Cancer Medicine, Institute of Translational Medicine, University of Liverpool, UK. Electronic address: ecostell@liverpool.ac.uk.
Cedars-Sinai Medical Center · USUniversity of Liverpool · GBJohns Hopkins University · USUniversity College London · GBThe Ohio State University Wexner Medical Center · USThe University of Texas MD Anderson Cancer Center · US

Funding

UCLA Clinical Translational Science InstituteUL1TR001881 · NCATS · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI ARLEEN F. BROWN, ARASH NAEIM · 2016 to 2026
$118.1M
Tumor Antigens for Individual Signatures and TherapyP50CA062924 · NCI · JOHNS HOPKINS UNIVERSITY · PI JAFFEE, ELIZABETH M. · 1993 to 2022
$54.6M
Clinical Validation Center for Early Detection of Pancreatic CancerU01CA200468 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI ANIRBAN MAITRA · 2016 to 2026
$11.0M
Transport Oncophysics CoreU54CA210181 · NCI · METHODIST HOSPITAL RESEARCH INSTITUTE · PI SHEN, HAIFA · 2016 to 2020
$9.3M
Pathophysiology, Epidemiology, and Prevention of Pancreatogenic Diabetes - Administrative SupplementU01DK108314 · NIDDK · CEDARS-SINAI MEDICAL CENTER · PI Mark Goodarzi, Stephen J. Pandol · 2015 to 2026
$6.1M
Imaging and Molecular Correlates of Progression in Cystic Neoplasms of the PancreasU01CA196403 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI MAITRA, ANIRBAN · 2015 to 2020
$5.8M
The Ohio State University Pancreatic Disorders Network (OSU-PDN)U01DK108327 · NIDDK · OHIO STATE UNIVERSITY · PI CONWELL, DARWIN LEWIS, HART, PHILIP A. · 2015 to 2024
$5.5M
PRedictiOn Algorithms for the DeTECTion of Early Stage Pancreatic Cancer (PRO-TECT)R01CA230442 · NCI · KAISER FOUNDATION RESEARCH INSTITUTE · PI WU, BECHIEN · 2019 to 2023
$4.0M
Translational Applications in an Animal Model of Pancreatic Cystic Neoplasm and CancerR01CA218004 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI MAITRA, ANIRBAN · 2018 to 2021
$2.4M
Predicting the diagnosis of pancreatic cancer by leveraging big dataR21CA220073 · NCI · CEDARS-SINAI MEDICAL CENTER · PI JEON, CHRISTIE YOUNGHAE · 2018 to 2019
$429k
Cancer Research UK 16791Cancer Research UK 26881Department of Health PB-PG-0712-28114Medical Research Council G0801588NCATS NIH HHS UL1 TR001881NCI NIH HHS P50 CA062924NCI NIH HHS R01 CA218004NCI NIH HHS R01 CA230442NCI NIH HHS R21 CA220073NCI NIH HHS U01 CA196403NCI NIH HHS U01 CA200468NCI NIH HHS U54 CA210181NIDDK NIH HHS L30 DK118657NIDDK NIH HHS U01 DK108314NIDDK NIH HHS U01 DK108327
6 · The paper itself

Abstract

Pancreatic ductal adenocarcinoma is most frequently detected at an advanced stage. Such late detection restricts treatment options and contributes to a dismal 5-year survival rate of 3-15%. Pancreatic ductal adenocarcinoma is relatively uncommon and screening of the asymptomatic adult population is not feasible or recommended with current modalities. However, screening of individuals in high-risk groups is recommended. Here, we review groups at high risk for pancreatic ductal adenocarcinoma, including individuals with inherited predisposition and patients with pancreatic cystic lesions. We discuss studies aimed at finding ways of identifying pancreatic ductal adenocarcinoma in high-risk groups, such as among individuals with new-onset diabetes mellitus and people attending primary and secondary care practices with symptoms that suggest this cancer. We review early detection biomarkers, explore the potential of using social media for detection, appraise prediction models developed using electronic health records and research data, and examine the application of artificial intelligence to medical imaging for the purposes of early detection.

Indexed as

AdultAgedAged, 80 and overArtificial IntelligenceBiomarkers, TumorCarcinoma, Pancreatic DuctalDeep LearningDiabetes Mellitus, Type 2Diagnostic ImagingEarly Detection of CancerElectronic Health RecordsFemaleGenetic Predisposition to DiseaseHumansMaleMass ScreeningBiomarkers, Tumor

Identifiers

PMID32135127
PMCPMC7380506
OpenAlexW2304258614

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.